View abstract

Cet abstract a été assigné à sessions

Type de présentation	E-poster
Titre	Improvement of Chorioretinal Folds after Teprotumumab in Severe Graves’ Orbitopathy

But	We report the case of a male in his forties, non-smoker, with biochemically proven active Graves’ orbitopathy (GO), with a clinical activity score (CAS) of 5/7 in the right and 1/7 in the left eye. Despite prompt treatment with thiamazole, β-blockers, selenium supplementation and intravenous methylprednisolone according to the EUGOGO guidelines, refractory disease was noted in the right eye, with a marked increase in swelling and proptosis, and a new finding of “curtain”-like, resulting in new onset metamorphopsia and visual loss. It is postulated that a combination of inflammation and choroidal venous congestion causes folding over Bruch’s membrane. Chorioretinal folds are a rare complication of GO, with only a handful of reported cases.
Méthodes	Because the patient preferred a deferral of orbital decompression, teprotumumab (TEPEZZA®), a novel insulin-like growth factor I receptor (IGF-IR) inhibitor, was initiated as second line treatment with four injections spaced three weeks apart.
Résultats	Preliminary results showed marked improvement in proptosis, CAS, metamorphopsia and vision with regression of chorioretinal folds. Therapy is well tolerated, with only mild hyperglycemia on the day of injection as a side effect. No hearing impairment was reported during treatment.
Conclusion	This case highlights the efficacy and excellent tolerance of teprotumumab (TEPEZZA®) in treating a severe GO presenting with a rare complication of chorioretinal folds.
Conflit d'intérêt	Non

Auteurs 1

Nom	JOOS
Initiales	B
Institut	Universitair Ziekenhuis Gent
Ville	Gent

Auteurs 2

Nom	Van Haecke
Initiales	H
Institut	Goes Oogcentrum
Ville	Antwerp

Auteurs 3

Nom	Van den Bruel
Initiales	A
Institut	AZ Sint-Jan
Ville	Brugge

Auteurs 4

Nom	Vandelanotte
Initiales	S
Institut	AZ Sint-Jan
Ville	Brugge